Targovax to fully focus on ONCOS oncolytic virus program
Oslo, Norway, 23 May 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that going forward the company will strengthen the commitment to oncolytic viruses and focus resources to advance the ONCOS program with full force. With the reporting of encouraging median overall survival and three-year survival rate, the TG01 trial in resected pancreatic cancer has been successfully completed (see press release here ). The